A new outbreak of Ebola in the Democratic Republic of Congo (DRC) has already caused the death of more than 2,000 people, according to data released on August 12, 2026. Infectious disease experts, such as David Wohl, physician and professor in the Division of Infectious Diseases at the University of North Carolina at Chapel Hill, warn about the severity of the humanitarian crisis on the African continent, although they reiterate that the risk of contamination for the population of countries such as the United States and, by extension, Brazil, remains very low. The current strain of the virus, known as Bundibugyo, has distinct genetic characteristics that make existing treatments and vaccines less effective.
The size of the Ebola outbreak and its particularities
The spread of the virus in the east and northeast of the Democratic Republic of Congo has been rapid and alarming. Government records point to a total of 4,381 confirmed cases, with cross-border occurrences in Uganda. The speed at which the disease spreads is unprecedented compared to previous outbreaks, reaching densely populated rural towns with hundreds of thousands of inhabitants.
“The outbreak is not happening in a town of 50 people, but in rural towns with hundreds of thousands of people,” said David Wohl. He further added that “the situation is worsening catastrophically, with more and more people becoming infected at a very fast pace, without much of a slowdown.” The Bundibugyo strain is mainly responsible for the current crisis, requiring specific therapeutic and preventive approaches.
More on this story: Health warning for July 4th holiday: necrotizing bacteria spreads and threatens beachgoers on US coast
Factors that make it difficult to control the disease in the DRC
Combating Ebola transmission in the Democratic Republic of Congo is challenging due to a combination of factors, described by David Wohl as a “perfect storm” of adverse conditions. These elements create a complex environment that impedes the rapid and effective response necessary to contain the virus.
- Key obstacles include:
- High population densities:The concentration of people in affected areas facilitates the spread of the virus.
- Limited access to remote regions:Reaching some communities with medical help is extremely difficult, delaying diagnosis and treatment.
- Armed conflicts:Instability and violence in outbreak areas complicate the entry and exit of health teams and the implementation of control measures.
- Difficulty in contact tracing:Monitoring people who have had contact with infected people becomes almost impossible in scenarios of great displacement and insecurity.
- Establishment of quarantines:Maintaining effective isolation protocols is a challenge in regions with scarce resources and limited infrastructure.
The low risk of Ebola contamination outside Africa
Despite the severity of the outbreak in Africa, health authorities emphasize that the likelihood of contracting Ebola for the general population, especially in countries with robust health systems, is minimal. Transmission of the virus requires direct physical contact with bodily fluids from a seriously ill or deceased individual, which limits spread to controlled hospital environments.
“I don’t think the average person needs to worry about contracting this here in the United States,” Wohl said, emphasizing that the virus does not spread through the air. For context, even during the massive Ebola outbreak in West Africa in 2014, which infected more than 28,000 people (the Zaire strain), only four cases were diagnosed in the US. Two were imported cases, and two nurses contracted the virus while caring for an infected patient in Dallas.
Furthermore, developed nations have much more effective public health systems, medical care and hygiene protocols to contain the disease. Viruses such as measles, influenza, Respiratory Syncytial Virus (RSV), and SARS-CoV-2 represent more pressing public health concerns for Americans, and Brazilians alike, than Ebola.
On the same topic: The size of an AirPods: technology allows accurate molecular tests at home
Challenges in developing treatments for the Bundibugyo variant
Medical researchers face significant obstacles due to different variants of the Ebola virus. Although treatments and vaccines were successfully developed against the Zaire strain during the 2014 crisis, the Bundibugyo variant, currently circulating in parts of the Democratic Republic of Congo, is genetically distinct. This crucial difference means that treatments approved for standard Ebola are neither effective nor approved for Bundibugyo-related illnesses.
Scientists and medical teams are actively evaluating new therapies and vaccine candidates specific to the Bundibugyo virus. Emerging technologies, such as mRNA platforms, are being explored to accelerate the development of vaccines targeting this specific viral threat. These efforts are crucial to providing an adequate response to the current strain.
Broader implications for global health and regional stability
For countries like the United States, the most relevant concerns regarding Ebola lie not with infection of the general population, but with potential risks to healthcare professionals traveling to Africa to assist with containment efforts. Furthermore, the instability that a major outbreak could generate in the region is a point of global attention, given the humanitarian crisis and geopolitical complexity.
David Wohl concluded that an average person who experiences symptoms such as a headache or fever does not need to worry that they may have Ebola. Surveillance and support for affected regions remains critical to protecting both local communities and global health security.